The supplied MCAD case
The transcript opens with the death of eight-month-old Sophia Williams after she became ill during a family holiday and stopped breathing on the flight home. The report states that she had an undetected genetic disorder, medium-chain acyl-CoA dehydrogenase deficiency, and that a stomach illness created a fatal metabolic crisis.
The lecture uses the case to explain the pathway logic. A person with MCAD deficiency cannot efficiently break down medium-chain fatty acids for energy. During prolonged fasting or illness, blood glucose can fall, ketone production is inadequate, harmful metabolites can accumulate, and lethargy can worsen feeding. The sequence can progress to seizures, coma, or death.
The case also introduces newborn screening as a prevention system. The transcript describes the family's call for screening and uses the event to show why a disorder that may be silent during ordinary feeding can become critical when energy demand changes.
Genetic disease and epigenetic regulation are not synonyms
The metabolic disorders in this chapter are presented as single-gene disorders in the supplied lecture and source book. A DNA-sequence variant changes a protein or enzyme, and the enzyme defect disrupts a pathway. That is a genetic mechanism.
Epigenetic regulation can change how strongly a gene is expressed without changing its sequence, but that does not convert every genetic disorder into an epigenetic disorder. The capstone value of metabolism is that it makes the sequence-to-function chain visible and clarifies the level at which a defect occurs.
| Disease | Defective enzyme | Accumulated | Deficient product | Consequences |
|---|---|---|---|---|
| PKU | Phenylalanine hydroxylase | Phenylalanine and phenylpyruvate | Tyrosine | Intellectual disability, eczema, and musty odor |
| MSUD | BCKDC | BCAAs and ketoacids | BCAA breakdown | Neurotoxicity, maple syrup odor, and coma |
| Galactosemia | GALT | Galactose-1-phosphate and galactitol | Glucose from galactose | Liver failure, E. coli sepsis, and cataracts |
| MCAD deficiency | MCAD | Medium-chain fatty acids | Ketone bodies | Hypoglycemia, seizures, and coma |
| Citrullinemia | ASS1 | Ammonia and citrulline | Urea | Hyperammonemia, lethargy, and coma |
| HFI | Aldolase B | Fructose-1-phosphate | Glucose intermediates | Hypoglycemia, vomiting, and liver or kidney damage |
| Question | What to identify | Why it matters |
|---|---|---|
| What gene is altered? | The inherited DNA defect | Locates the primary sequence-level cause |
| What protein or enzyme is affected? | Missing, reduced, or dysfunctional activity | Identifies the blocked reaction |
| What accumulates? | Substrate or alternative byproducts | Explains toxicity and diagnostic markers |
| What is deficient? | Downstream product or energy output | Explains functional failure |
| When does risk rise? | Feeding, fasting, illness, or metabolic stress | Connects pathway state with clinical presentation |